Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy.
- Published In:
- Exploration of targeted anti-tumor therapy, 4(3), 396-405 (2023)
- Authors:
- Hentzen, Stijn, Mehta, Kathan, Al-Rajabi, Raed Moh'd Taiseer, Saeed, Anwaar, Baranda, Joaquina Celebre, Williamson, Stephen K, Sun, Weijing, Kasi, Anup
- Database ID:
- RPEP-06950
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06950APA
Hentzen, Stijn; Mehta, Kathan; Al-Rajabi, Raed Moh'd Taiseer; Saeed, Anwaar; Baranda, Joaquina Celebre; Williamson, Stephen K; Sun, Weijing; Kasi, Anup. (2023). Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy.. Exploration of targeted anti-tumor therapy, 4(3), 396-405. https://doi.org/10.37349/etat.2023.00141
MLA
Hentzen, Stijn, et al. "Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy.." Exploration of targeted anti-tumor therapy, 2023. https://doi.org/10.37349/etat.2023.00141
RethinkPeptides
RethinkPeptides Research Database. "Real world outcomes in patients with neuroendocrine tumor re..." RPEP-06950. Retrieved from https://rethinkpeptides.com/research/hentzen-2023-real-world-outcomes-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.